Scientists say the inactivated samples posed no infection risk but may have breached US import-declaration rules. Critics see a prosecution driven by politics; defenders of the rules say shortcuts cannot stand.
A criminal case against two virologists at the US National Institutes of Health has hardened into a national flashpoint over biosecurity, scientific mobility and the politics of pathogen research. Vincent Munster, who heads the virus ecology section at the National Institute of Allergy and Infectious Diseases, and Claude Kwe, a research fellow in his group, face charges arising from biological samples they were carrying when they arrived in Detroit, Michigan, in January 2026 after nine days of fieldwork in the Republic of the Congo, where a monkeypox outbreak was under way.
The US Department of Justice, through the Eastern District of Michigan, charged the pair on 2 June with conspiring to smuggle biological material and making false statements to federal officers. Both have pleaded not guilty. According to the federal complaint, Munster, when questioned at the airport, denied carrying any biological materials and described the contents of the case as diagnostics. Federal testing completed by 29 May found that the samples contained monkeypox virus DNA but that none were infectious.
The regulatory nuance
That last detail is the crux of the scientific dispute. Inactivated viral samples of this kind do not require an import permit, but they must be declared to federal officials, and inactivated material also requires a certification of deactivation. The complaint alleges that Munster and Kwe neither declared the samples truthfully nor produced the required certification, and that they attempted to present the material as unused diagnostics. Munster, who himself helped design protocols to inactivate the virus, reportedly told border officers that the necessary documents were on his laptop; the complaint does not establish whether they were. If convicted, the scientists face a maximum sentence of five years.
A political charge
The case has not stayed in the courtroom. It is the latest in a series of prosecutions of researchers over biological samples, and it has drawn the NIH’s Rocky Mountain Laboratories in Hamilton, Montana, into a wider political contest over the oversight of pathogen research. On 5 June, Senator Rand Paul of Kentucky, a persistent critic of former NIAID director Anthony Fauci, released dozens of pages of emails between Munster and other scientists, arguing they revealed a pattern of lax sample handling; one 2011 message discussed hand-carrying samples on a commercial flight, though it does not establish that this occurred. Senator Tom Cotton of Arkansas has backed legislation to impose severe sentences for smuggling biological agents, warning that illegally moving dangerous viruses threatens public health. Members of Congress have called for an investigation of the laboratory.
Scientists divided
Within the research community, reaction has split along a revealing line, not over the facts of infectiousness, which are largely agreed, but over the seriousness of the procedural breach. Angela Rasmussen, a virologist at the University of Saskatchewan, argued that properly inactivated virus is inert, writing that a person could drink such a sample and not become infected. Others insist the point is procedural, not biological. Melanie Ott, who heads the Gladstone Institutes in San Francisco, acknowledged the logistical difficulty of moving samples but maintained that the regulations have to be followed. Jean-Paul Gonzalez, a biosecurity specialist at Georgetown University, called carrying even inactivated samples on a commercial flight a mistake, noting that the practice was abandoned by the field years ago.
The chilling effect
Several US-based virologists who routinely import pathogen samples would speak only off the record, citing fear of professional repercussions, an indication of how sharply the climate has shifted. That anxiety is the story’s quieter but larger dimension. Field virology depends on moving samples across borders quickly, often from outbreak zones with limited infrastructure, and the discipline’s value lies precisely in tracking emerging pathogens before they spread. A prosecution that many scientists read as disproportionate risks deterring exactly the cross-border collaboration that early outbreak response requires.
The case now moves through the courts. Kwe has had an initial hearing; Munster is scheduled to appear on 22 July. Its resolution will matter beyond the two defendants, because it is being watched as a signal of how far US authorities intend to police the movement of biological materials, and of whether legitimate concerns about import compliance can be separated from the politics that have attached themselves to the NIH.
–Rithvisha Kiran
